Zenas BioPharma, Inc. Common Stock (ZBIO NASDAQ) stock market data APIs
$9.5643
0.52(5.4%)
as of May 30, 2025
Try our APIs with
free plan!
Zenas BioPharma, Inc. Common Stock Financial Data Overview
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Prev. Close
9.5643
Open
10.0857
High
10.0857
Low
9.2985
52 wk Range
5.83-26.251
Market Cap
461 M
Shares Outstanding
41 834 K
Revenue
15 000 K
EPS
-0.8
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Zenas BioPharma, Inc. Common Stock data using free add-ons & libraries
Get Zenas BioPharma, Inc. Common Stock Fundamental Data
Zenas BioPharma, Inc. Common Stock Fundamental data includes:
- Net Revenue: 15 000 K
- EBITDA: -173 512 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-15
- EPS/Forecast: -1.03
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Zenas BioPharma, Inc. Common Stock News
New
Levi & Korsinsky Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 – ZBIO
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities la...
ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or trace...
ZBIO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit
SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Ze...
The Gross Law Firm Notifies Shareholders of Zenas BioPharma, Inc. (ZBIO) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
